These findings implicate that Piezo1 has potential to serve as an independent prognostic marker for HCC patients after liver resection, which might facilitate precision medicine, helping to predict the prognosis, direct the individualized therapy or act as a therapeutic target. The gene discussed is PIEZO1; the disease is hepatocellular carcinoma.